One-stop solution for bsAb discovery
Compatible with almost any mAb and sdAb sequence
Bispecific antibodies(bsAb) are artificial antibodies containing two specific antigen binding sites, and their novel mechanism of action(MOA) have been shown better efficacy and higher safety compared to monoclonal antibodies. Based on clinical results, bsAb has shown better therapeutic efficacy compared with combination treatment. BsAb has become a R&D trend in recent years for the treatment of various diseases like cancer, inflammation, viral infections, and autoimmune diseases.
BsAb can be classified into four main categories based on MOA: cell-engager, dual target blockade, dual immunomodulators and cell surface protein bridging. It can also be divided into bispecific IgG and bsAb fragment based on whether containing Fc domain. The bsAb formats affect the efficacy and safety. The target and MOA are important consideration for bsAb discovery.
Extensive experience in major bsAb formats, ProBio provides one-stop bsAb discovery from target validation to preclinical candidates(PCC) , including bsAb format design for different MOA and target , bsAb construction and expression, functional validation, in vivo assay and developability.
Download the flyer to learn more about our bispecific antibody discovery service ➡
Excellent bsAb track record
By Dec 2022
Customized bsAb format
One-stop bsAb discovery solution
Knob into hole(KIH)
Mutate one Thr in the CH3 region of one H chain to Tyr, forming a prominent "Knobs" structure, while one larger Tyr residue in the CH3 region of the other H chain is mutated to a smaller Thr, forming a concave "holes" structure. The steric hindrance effect of this structure can achieve correct assembly between two different H chains.
Based on the "Knob into hole (KIH)" structure, the CH1 and CL of the Fab region are switched to reduce L chain mismatch.
IgG fused with scFv
Bispecificity is achieved by fusing two single-chain antibodies (scfv) to a normal IgG antibody. Pairs of scfv can be attached to the C-terminus or N-terminus of each L or H chain, and the specificity of each scfv can be the same or different.
The VL and VH domains of one Ab are attached to the N-terminus of each Fab arm of one normal IgG Ab respectively, resulting in a tetravalent molecule with two binding sites for each antigen. DVD-Ig can achieve bispecificity through two variable regions binding dual targets. This technique avoids mismatching of different H/L chains.
GenScript ProBio SMABodyTM(Single-domain antibody fused to mAb) platform combines naturally generated single domain antibody and monoclonal antibody(mAb) to form a bispecific antibody in symmetric format with good biological efficacy and good developability，it only needs 3-5 month for SMABody™ screening & evaluation.
Contact us now for more detailed information.
I agree to receive the latest news, information, promotions, webinars and services, and acknowledge that I can opt out any time.